Use of invasive ergometric exercise to assess the hemodynamic response to XXXX .

@entity1 @entity712 @entity7236 @entity101 @entity26 @entity3360 @entity460 @entity544
The @entity460 antagonists are potent vasodilators. This physiologic property suggests that these agents have a potential role in the treatment of @entity1 with @entity101 and @entity712 . Although the clinical response to @entity460 antagonism in @entity101 is promising, the response in @entity1 with @entity712 is less than hoped for; this is due to the fact that this class of agents may induce a hemodynamically important degree of negative inotropic effect. To test the hemodynamic response to @entity3360 , a second-generation @entity7236 , the hemodynamic response to maximal ergometric exercise was evaluated in a group of @entity1 with moderate to severe chronic @entity712 . One week of @entity3360 therapy was associated with a significant reversal of vasoconstriction at rest and during peak exercise with a secondary increase of cardiac index, and a decrease in pulmonary wedge pressure. The reversal of vasoconstriction was associated with a decrease in mean arterial pressure, with no change in the heart rate. There was no change in @entity26 consumption or @entity544 production; however, there was a decrease in arteriovenous @entity26 difference, consistent with a reduction of @entity26 extraction. This short-term study identified the potent vasodilator properties of @entity3360 in @entity1 with chronic @entity712 ; a hemodynamically significant negative inotropic effect could not be identified. Although the use of @entity460 antagonists for the treatment of @entity712 may have a limited role, this study nonetheless suggests that @entity3360 may have a favorable vasodilator effect without an overt negative inotropic effect. This would be of considerable advantage in the treatment of @entity101 , when compared with beta-adrenergic blocking agents.
